| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/27/2003 | WO2003016563A2 Novel molecular target for neurotoxicity |
| 02/27/2003 | WO2003016549A2 Nucleic-acid associated proteins |
| 02/27/2003 | WO2003016528A2 Oligonucleotide compositions and their use to induce apoptosis |
| 02/27/2003 | WO2003016522A2 Methods and compounds for the targeting of protein to exosomes |
| 02/27/2003 | WO2003016506A2 Secreted proteins |
| 02/27/2003 | WO2003016493A2 Transporters and ion channels |
| 02/27/2003 | WO2003016472A2 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 02/27/2003 | WO2003016466A2 ANTI-Aβ ANTIBODIES |
| 02/27/2003 | WO2003016350A1 A method of producing antibodies ex-vivo |
| 02/27/2003 | WO2003016335A2 Irreversible cysteine protease inhibitors of legumain |
| 02/27/2003 | WO2003016334A1 Methods for purification of an activated peg solution and for the synthesis of a modified hemoglobin solution |
| 02/27/2003 | WO2003016326A1 Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient |
| 02/27/2003 | WO2003016316A1 Diazacycloalkanes as oxytocin agonists |
| 02/27/2003 | WO2003016315A1 Sodium salt of an hiv integrase inhibitor |
| 02/27/2003 | WO2003016314A1 1-alkyl 0r 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/27/2003 | WO2003016313A1 New compounds for treating impotence |
| 02/27/2003 | WO2003016310A1 Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders |
| 02/27/2003 | WO2003016305A1 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
| 02/27/2003 | WO2003016291A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ |
| 02/27/2003 | WO2003016279A1 Fused-polycyclic compounds |
| 02/27/2003 | WO2003016277A1 Cyclohept`b!indole derivatives as spla2 inhibitors |
| 02/27/2003 | WO2003016275A1 Antiviral agent |
| 02/27/2003 | WO2003016273A2 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 02/27/2003 | WO2003016270A2 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003016269A1 5-amidino-n-(2-aminophenethyl)-n-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 02/27/2003 | WO2003015872A2 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders |
| 02/27/2003 | WO2003015820A1 GnRH AGONIST COMBINATION DRUGS |
| 02/27/2003 | WO2003015810A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 02/27/2003 | WO2003015807A1 Side effct-relieving agents and/or hypoglycemic effect enhancers for thiazolidine derivatives |
| 02/27/2003 | WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | WO2003015794A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | WO2003015792A1 Anti-tumour 2-alkoxyestradiol sulfamates |
| 02/27/2003 | WO2003015790A1 Thiopyrane-4-ones as dna protein kinase inhibitors |
| 02/27/2003 | WO2003015787A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | WO2003015785A1 2h-phthalazin-1-ones and methods for use thereof |
| 02/27/2003 | WO2003015784A1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors |
| 02/27/2003 | WO2003015780A2 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease |
| 02/27/2003 | WO2003015775A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 02/27/2003 | WO2003015774A1 Compounds effecting glucokinase |
| 02/27/2003 | WO2003015773A2 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases |
| 02/27/2003 | WO2003015772A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | WO2003015770A1 Novel combination |
| 02/27/2003 | WO2003015765A1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect |
| 02/27/2003 | WO2003015762A1 Remedial agent for cardiac failure |
| 02/27/2003 | WO2003015761A1 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003015759A2 Treatment of hyperproliferative conditions of body surfaces |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015755A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | WO2003015753A1 Liposome preparations |
| 02/27/2003 | WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | WO2003015744A1 Chitin microparticles and their medical uses |
| 02/27/2003 | WO2003015729A1 Topical composition for follicular delivery of an ornithine decarboxylase inhibitor |
| 02/27/2003 | WO2003015705A2 In situ immunization |
| 02/27/2003 | WO2003015704A2 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 02/27/2003 | WO2003015689A2 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 02/27/2003 | WO2003015612A2 Materials and methods to promote repair of nerve tissue |
| 02/27/2003 | WO2003015608A2 Combination therapy for the treatment of cancer |
| 02/27/2003 | WO2003015516A1 Compositions and methods for treatment of mitochondrial diseases |
| 02/27/2003 | WO2003015494A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | WO2003004098A8 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 02/27/2003 | WO2003002123A3 Therapeutic combinations for the treatment of hormone deficiencies |
| 02/27/2003 | WO2003001881A3 Cell-based high-throughput screening methods |
| 02/27/2003 | WO2003000656A3 Antisense modulation of transforming growth factor beta receptor ii expression |
| 02/27/2003 | WO2002102777A3 NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE |
| 02/27/2003 | WO2002100862A3 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 02/27/2003 | WO2002100348A3 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 02/27/2003 | WO2002099037A3 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| 02/27/2003 | WO2002098865A3 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
| 02/27/2003 | WO2002098413A3 Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof |
| 02/27/2003 | WO2002098350A3 Pyranoindazoles and their use for the treatment of glaucoma |
| 02/27/2003 | WO2002098278A3 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 02/27/2003 | WO2002096398A3 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus |
| 02/27/2003 | WO2002095704A9 Use of nf-kappa-b inhibitors to treat dry eye disorders |
| 02/27/2003 | WO2002094180A3 Pharmaceutically active isoindoline derivatives |
| 02/27/2003 | WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/27/2003 | WO2002090325A3 Benzazepinone alpha v integrin receptor antagonists |
| 02/27/2003 | WO2002089749A3 Arylsulfonamide ethers, and methods of use thereof |
| 02/27/2003 | WO2002089740A3 Sulfonamides |
| 02/27/2003 | WO2002088172A3 Pentapeptide compounds and uses related thereto |
| 02/27/2003 | WO2002087511A3 Modulators of elastase inhibitor secretion |
| 02/27/2003 | WO2002087472A8 Stent-based delivery of statins to prevent restenosis |
| 02/27/2003 | WO2002087423A3 Carbonic anhydrase activators for enhancing learning and memory |
| 02/27/2003 | WO2002085903A3 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 02/27/2003 | WO2002083064A3 A method of treating cancer |
| 02/27/2003 | WO2002074042A3 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 02/27/2003 | WO2002072542A3 Ph-dependent nmda receptor antagonists |
| 02/27/2003 | WO2002072012A3 A novel proteosome-liposaccharide vaccine adjuvant |
| 02/27/2003 | WO2002067869A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/27/2003 | WO2002066420A3 Tryptase inhibitors |
| 02/27/2003 | WO2002064590A3 Carboline derivatives |
| 02/27/2003 | WO2002060951A3 Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| 02/27/2003 | WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| 02/27/2003 | WO2002055022A3 Active metabolite of antifungal compound |
| 02/27/2003 | WO2002049577A3 Analogues of thiocoraline and be-22179 |
| 02/27/2003 | WO2002046193A3 Heterocyclic ether substituted imidazoquinolines |
| 02/27/2003 | WO2002028865A3 Condensed pyridoindole derivatives |
| 02/27/2003 | WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 02/27/2003 | WO2002020767A3 G-csf analog compositions and methods |
| 02/27/2003 | WO2002020000A3 Combined estrogen blockade of the breast with exemestane and raloxifene |